Dyslipidemia and Cardiovascular Risk in Psoriatic Arthritis: The Role of JAK Inhibitors and the Need for Lipid Monitoring

Farzana Shumy, Kotaro Matsumoto

Open source

DOI
10.1111/1756-185x.70102
Published
2025-02
Container
International Journal of Rheumatic Diseases
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/1756-185x.70102,
  title = {Dyslipidemia and Cardiovascular Risk in Psoriatic Arthritis: The Role of JAK Inhibitors and the Need for Lipid Monitoring},
  author = {Farzana Shumy and Kotaro Matsumoto},
  year = {2025},
  journal = {International Journal of Rheumatic Diseases},
  doi = {10.1111/1756-185x.70102},
  url = {https://doi.org/10.1111/1756-185x.70102}
}

RIS

TY  - JOUR
TI  - Dyslipidemia and Cardiovascular Risk in Psoriatic Arthritis: The Role of JAK Inhibitors and the Need for Lipid Monitoring
AU  - Farzana Shumy
AU  - Kotaro Matsumoto
PY  - 2025
JO  - International Journal of Rheumatic Diseases
DO  - 10.1111/1756-185x.70102
UR  - https://doi.org/10.1111/1756-185x.70102
ER  - 

APA

Shumy, F., & Matsumoto, K. (2025). Dyslipidemia and Cardiovascular Risk in Psoriatic Arthritis: The Role of JAK Inhibitors and the Need for Lipid Monitoring. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70102

Source records